CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 65 enrolled
Drug / intervention
Beta-lactam antibioticdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03033394
NCT03033394N/ACompleted

Defining Adult Beta-lactam Antimicrobial Pharmacokinetics Across the Secondary Care Setting

Imperial College London·observational·Posted Jan 26, 2017·Updated Aug 30, 2021

In Brief

An observational study evaluating Beta-lactam antibiotic for Pharmacokinetics and 2 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

Currently in the UK, TDM is routinely performed for aminoglycosides and glycopeptide antimicrobial agents, given fears over the narrow therapeutic window of these agents and the serious adverse events associated with toxicity. However, in critical care the role of TDM for optimisation of therapy has been demonstrated to help optimise dosing of patients who tend to have variable pharmacokinetic parameters (J. A. Roberts et al,). This is of growing importance given that low concentrations of antimicrobial agents, below a micro-organisms minimum inhibitory concentration (MIC) is believed to be a major driver of AMR. The investigators set out to explore whether similar observations in PK-PD target variability are currently being observed across the secondary care setting (outside of critical care) and whether these appear to be impacting on clinical outcomes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 26, 2017
Enrollment StartJul 12, 2017
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.4 years ago

Interventions

Beta-lactam antibioticdrug

Routine clinical dosing